Last updated Jun 6, 2026
United Therapeutics
Evidence Sources
6
Competitive Findings
0
Portfolio Developments
0
Regulatory Precedents
3
Clinical Programs
1
Confidence Coverage
72%
Audit
- Competitor findings: 0
- Portfolio developments: 0
- Self-competition findings removed: 0
- Unknown ownership findings removed: 0
Executive Summary
Material intelligence activity detected across:
- Pulmonary Arterial Hypertension
- Prostacyclin Analog
Highest priority development: Regulatory Developments Enhance Competitive Landscape for Tyvaso in PAH Market
Competitive pressure: Low
Portfolio impact: Moderate
Evidence coverage: 72%
Active Signals
1
Investigate Priority
0
Opportunity Score
24
Buyer Quality
8 · Mid-Market
Recent Signals
Latest intelligence events linked to this organization.
- MonitorJun 6, 2026Score 24FDA Accepts Supplement Application for Tyvaso (Treprostinil)
Pulmonary Arterial Hypertension · Prostacyclin Analog
Related Assets
Portfolio asset pages with evidence-based assessments.
- Regulatory Developments Enhance Competitive Landscape for Tyvaso in PAH MarketModerate Confidence · 78%
Portfolio asset at Approved stage
Sources (3)AutoResearchCompetitivaRegunera
Portfolio Development
Owned-asset pipeline events — Phase III readouts, approvals, label expansions, and deals. Not classified as competitive threats.
No portfolio development items are linked to this company yet.
Competitive Intelligence Findings
Competitiva findings with evidence, reasoning, and confidence calibration.
No Competitiva findings are linked to this company yet.
Regulatory Developments
Regunera precedents with source attribution and confidence disclosure.
- FDA AP — BAXFENDY (ORIG)Moderate Confidence · 77%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - FDA AP — TYVASO (SUPPL)Moderate Confidence · 77%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - [IBENTO][IBENTO]PMDA-ATC GMP Inspection Seminar 2026 applications openLow Confidence · 54%
Regulatory precedent may inform portfolio positioning
Sources (3)PMDAPMDARegunera
Clinical Developments
Pipeline activity with auditable evidence and uncertainty disclosure.
- Regulatory Developments Enhance Competitive Landscape for Tyvaso in PAH MarketModerate Confidence · 76%
Clinical program tracked via asset intelligence
Sources (2)AutoResearchClinicalTrials.gov
Investigate-Priority Items
Signals flagged for investigation or escalation — highest urgency for portfolio review.
No investigate-priority signals are active for this company.
Humanexa Agent Questions
Suggested prompts to explore this organization's intelligence profile. Open a linked signal to ask the agent.
- What are the most material competitive threats to United Therapeutics right now?
- Which regulatory precedents should United Therapeutics monitor in Pulmonary Arterial Hypertension and Prostacyclin Analog?
- How does Regulatory Developments Enhance Competitive Landscape for Tyvaso in PAH Market compare to the nearest competitive programs?
- What signals require immediate investigation for United Therapeutics?
- Summarize the strategic implications of recent developments for United Therapeutics.
- Where is the greatest uncertainty in United Therapeutics's competitive positioning?